KOSDAQBiotech & Pharma195990

Abpro Bio

₩1,129▼ 0.53%2026-10-02 close

Market Cap

₩18.4B

Turnover

₩10,828,577

Volume

9,594 shares

Shares out.

16.3M

PER

—

PBR

0.7×

EPS

-₩178

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Third Pivot: From Biotech to Entertainment

RootK, which started as a machining-center maker and has since moved through biotech and semiconductor equipment into entertainment and logistics, is simultaneously pursuing a capital reduction, rights offering and convertible bond issuance amid capital-impairment concerns from accumulated net losses.

1
Consolidated revenue rose for four straight years, from KRW 22.1bn in 2022 to KRW 31.9bn in 2025, while operating losses continued every year.
2
The 2025 net loss widened sharply to KRW -48.9bn from KRW -15.6bn a year earlier, with most of it concentrated in a single quarter (Q2 2025) that appears to reflect a large one-off charge.
3
Cumulative losses shrank total equity for three straight years, from KRW 140.2bn in 2022 to KRW 54.0bn in 2025, raising capital-impairment concerns.
4
Following a change of controlling shareholder in April 2026, the company approved articles-of-incorporation amendments renaming itself RootK and adding numerous entertainment, video and logistics business purposes.
5
Common shares were suspended from trading starting July 10, 2026 due to share consolidation from the capital reduction, with the timing of the new-share relisting the next item to confirm.

Business structure

RootK (formerly Abpro Bio, and before that Yujin T-Int) listed on KOSDAQ in 2015 as a maker of small CNC machining centers before going through two subsequent shifts in business identity.

In 2019 the company acquired from Abpro Corporation of the United States the rights to develop and commercialize the bispecific antibodies ABP-100 (HER2 x CD3) and ABP-201 (VEGF x ANG-2) across 48 countries including all of Asia, CIS states and the Middle East, marking its entry into biotech drug development.

In 2023 it broadened its scope further by bringing subsidiary ANH into the fold for display and semiconductor equipment and module-process business tied to secondary battery manufacturing.

Revenue is still understood to be generated mostly by the legacy machining and equipment business, while the biotech segment has yet to contribute any sales, as its programs remain pre-clinical.

Following a change of controlling shareholder to 'Returns' in April 2026, the company added a large number of entertainment, content and logistics business purposes, and at an extraordinary general meeting on June 12 approved changing its name to RootK.

The new controlling shareholder Returns is majority-owned by an individual connected to entertainment and content businesses, and is linked through affiliates to a stake held by Cube Entertainment.

This series of business reorganizations has produced a composite structure in which machining, biotech, semiconductor equipment, entertainment and logistics all coexist under one company.

In terms of competitive positioning, each segment belongs to a distinct industry -- precision machining, drug development, semiconductor back-end processes and content -- making direct peer comparison within a single sector difficult.

Earnings trend

Quarterly revenue · Operating profit

₩9.1B-₩2.5B25Q2₩7.9B-₩1.7B25Q3₩6.1B-₩1.8B25Q4₩7.9B-₩2.3B26Q1₩9B-₩4.1B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩22.1B-₩8.6B2022₩25.4B-₩8.8B2023₩31.7B-₩10.2B2024₩31.9B-₩9.3B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩9.1B	-₩2.5B	−27.7%
2025Q3	₩7.9B	-₩1.7B	−21.6%
2025Q4	₩6.1B	-₩1.8B	−29.6%
2026Q1	₩7.9B	-₩2.3B	−28.7%
2026Q2	₩9B	-₩4.1B	−45.6%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩22.1B	-₩8.6B	-₩8.1B	−38.9%	−5.8%	11.7%
2023	₩25.4B	-₩8.8B	-₩25.7B	−34.7%	−21.0%	16.2%
2024	₩31.7B	-₩10.2B	-₩15.6B	−32.2%	−14.5%	30.8%
2025	₩31.9B	-₩9.3B	-₩48.9B	−29.1%	−90.5%	38.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-05

Earnings analysis

Consolidated revenue rose for four consecutive years, from KRW 22.1bn in 2022 to KRW 25.4bn in 2023, KRW 31.7bn in 2024 and KRW 31.9bn in 2025.

Operating losses, however, persisted every year over the same period at KRW -8.6bn, -8.8bn, -10.2bn and -9.3bn respectively; the operating margin improved somewhat from -38.9% in 2022 to -29.1% in 2025 but remained deeply negative.

Net losses were far more volatile, swinging from KRW -8.1bn in 2022 to KRW -25.7bn in 2023 and KRW -15.6bn in 2024 before hitting KRW -48.9bn in 2025, the largest of the four years.

On a quarterly basis, most of the 2025 net loss (roughly KRW -44.4bn) was concentrated in a single quarter, Q2 2025, where revenue was KRW 9.1bn and the operating loss KRW -2.5bn -- a gap suggesting a large one-off charge unrelated to core operating performance.

Net losses then narrowed noticeably in Q3 2025 (KRW -0.2bn) and Q4 2025 (KRW -1.1bn), and Q1 2026 turned to a net profit of KRW 2.1bn on revenue of KRW 7.9bn, the first profitable quarter in the window.

In Q2 2026, however, revenue grew to KRW 9.0bn yet the operating loss widened to KRW -4.1bn, the largest in this stretch, and the net loss swung back to KRW -5.8bn, indicating the earnings recovery has not yet become a stable trend.

Total equity fell for three consecutive years, from KRW 140.2bn in 2022 to KRW 122.3bn in 2023, KRW 108.0bn in 2024 and KRW 54.0bn in 2025, showing accumulated net losses eroding shareholders' equity rapidly.

Operating cash flow was also negative in all four years (from KRW -12.5bn to KRW -4.9bn), underscoring a continued reliance on external financing rather than internally generated cash.

Industry analysis

The domestic small machining-center and machine-tool market is tied to precision-machining demand for smartphones and electronic components as well as the trend toward lightweighting in finished vehicles, with growing demand for aluminum machining for Apple iPhone cases cited as a recent demand driver.

Demand for precision machining and module processes related to secondary battery and EV components is also seen expanding gradually.

In biotech, competition to develop bispecific antibody therapeutics is intense both domestically and globally, but RootK's licensed assets -- ABP-100 at the IND-filing stage for a Phase 1 trial and ABP-201 still pre-clinical -- remain at an early stage of development compared with larger developers that have already entered clinical trials.

Moreover, reports that business at Abpro Corporation, the U.S. source of the licensed rights, has been shrinking raise additional questions about the sustainability of the domestic licensing business.

The semiconductor and display equipment segment (ANH) competes with domestic small and mid-sized equipment makers, an industry characterized by heavy reliance on specific customers and order cycles.

The newly declared entertainment, content and logistics businesses represent an as-yet-unmonetized new area in which the company is a latecomer competing against already-established content and entertainment specialists.

Outlook

In March 2026 the company decided on a capital reduction to offset accumulated deficits via an ordinary resolution of shareholders, proceeding under provisions of the Commercial Act that allow the creditor-objection procedure to be omitted.

As a result, common-share trading was suspended from July 10, 2026 due to the electronic registration change and cancellation associated with the share consolidation, with the suspension disclosed as running until the day before the new shares are relisted.

The company has stated it plans to pursue a rights offering and convertible bond issuance alongside the capital reduction, combining balance-sheet repair with new fundraising.

On the business side, the June extraordinary general meeting approved changing the company name to RootK and adding numerous entertainment, video and logistics business purposes, making concrete monetization plans and results in this area a key point to watch going forward.

The legacy biotech drug-development business still has outstanding milestones to confirm, including the IND filing for ABP-100's Phase 1 trial and the progress of ABP-201's pre-clinical work.

The machining and semiconductor equipment segments continue to show revenue growth, but how investment and personnel are reallocated between legacy businesses and the new areas amid the reorganization also remains to be seen.

Valuation

PER

—

PBR

0.7×

ROE

-8.9%

EPS

-₩178

BPS

₩1,819

Dividend per share

₩0

The current share price is understood to trade below the company's own calculated book value per share, a pattern that reflects the balance-sheet reality of total equity shrinking rapidly from accumulated net losses.

Because net income has been chronically negative, earnings-based valuation metrics have limited applicability, and the market appears to weigh other yardsticks such as book value or expectations around the business reorganization instead.

No dividend was paid in the most recent fiscal year, so the capacity for shareholder returns via dividends is currently limited. The simultaneous capital reduction, rights offering and convertible bond issuance also mean that per-share value metrics themselves could be reset as the share count changes going forward.

With the business reorganization now in full swing, whether profitability improves in the legacy machining and equipment businesses and whether the new businesses generate visible revenue are likely to be the yardsticks the market applies going forward.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-05

Bull factors

Four straight years of revenue growth

Consolidated revenue grew for four consecutive years, from KRW 22.1bn in 2022 to KRW 31.9bn in 2025, while the operating margin also improved somewhat from -38.9% to -29.1% over the same period.

Expanding demand for aluminum machining tied to iPhone cases and precision machining tied to secondary battery and EV components appear to have supported this revenue growth. That said, operating losses themselves have persisted, so top-line growth has not fully translated into improved profitability.

Attempted balance-sheet normalization

In March 2026 the company resolved a capital reduction to offset accumulated deficits and has stated plans to pursue a rights offering and convertible bond issuance in parallel to address capital-impairment concerns and raise new funds.

If completed as planned, these steps would remove the company from book-value capital impairment and add some financial headroom. The completion timeline, fundraising terms and actual use of proceeds have not yet been finalized, however.

Portfolio diversification via new businesses

New controlling shareholder Returns is majority-owned by an individual connected to entertainment and content businesses, and is linked through affiliates to a stake held by Cube Entertainment.

The company has renamed itself RootK and added numerous entertainment, video and logistics business purposes, seeking new revenue sources beyond its legacy machining, biotech and semiconductor equipment operations.

These new businesses remain at an early, unmonetized stage, however, and actual results will need to be confirmed through future disclosures.

Bear factors

Capital-impairment concerns from accumulated losses

Total equity fell for three consecutive years, from KRW 140.2bn in 2022 to KRW 54.0bn in 2025, and the 2025 net loss of KRW -48.9bn was more than triple the prior year's loss.

This accumulation of losses has raised capital-impairment concerns, prompting the company to pursue a capital reduction, rights offering and convertible bond issuance simultaneously. If losses of similar magnitude recur, the balance-sheet repair achieved through these steps could be undone again.

Frequent shifts in business identity and management

The company has repeatedly changed its business identity, moving from machining to biotech drug development, then to semiconductor equipment, and most recently to entertainment and logistics. Its CEO has changed multiple times, and the controlling shareholder has also changed again recently. Such repeated pivots can raise questions about execution capability and strategic consistency.

Stalled biotech pipeline and related-party risk

ABP-100 remains at the IND-filing stage for a Phase 1 trial and ABP-201 is still pre-clinical, so no visible clinical progress has yet materialized.

Reports that business at Abpro Corporation, the U.S. source of the licensed rights, has been shrinking also raise questions about the sustainability of the domestic licensing arrangement itself.

With the biotech segment contributing no revenue, further swings in the value of related assets could add to earnings volatility.

Risk factors

Listing-eligibility and capital-impairment risk

In response to capital-impairment concerns, the company is simultaneously pursuing a capital reduction, rights offering and convertible bond issuance, and share trading has been suspended since July 2026 due to the share consolidation.

If these procedures are delayed or their terms turn unfavorable, uncertainty around continued listing requirements could persist. Should losses recur, the risk of renewed capital impairment cannot be ruled out.

Business-reorganization execution risk

The newly added entertainment, content and logistics business purposes have not yet translated into revenue, and the company's actual capabilities and competitiveness in these areas remain unverified.

If resources are not properly allocated between the legacy machining and semiconductor equipment businesses and the new ventures, the competitiveness of the existing businesses could be undermined instead.

Dilution and governance risk

If the rights offering and convertible bond issuance proceed as planned, existing shareholders' equity stakes could be diluted.

Given that the controlling shareholder has changed several times in recent years and CEO turnover has also been frequent, uncertainty around governance stability and consistency of management decision-making also exists.

What to watch next

September-October 2026
Confirm the timing of the new-share relisting and resumption of trading following the share consolidation; any delay would directly affect liquidity.
November 2026
Check the Q3 2026 quarterly report when disclosed, reviewing revenue and profit trends and whether the new entertainment/logistics businesses have begun contributing revenue.
Second half of 2026
Confirm disclosure of finalized terms for the rights offering and convertible bond issuance, checking the issue price, size, resulting dilution and intended use of proceeds.
Second half of 2026
Monitor disclosures on biotech pipeline progress, including whether ABP-100's IND filing for a Phase 1 trial is submitted.
Upcoming quarterly earnings releases
Confirm whether the newly added entertainment, video and logistics business purposes translate into actual reported revenue, and if so, what proportion of sales they represent.

Overall view

RootK has continually expanded its business scope from machining equipment into biotech drug development, semiconductor equipment, and most recently entertainment and logistics, undergoing multiple identity shifts in a short span of time.

Revenue grew for four consecutive years, but operating losses persisted every year, and 2025 saw a large one-off charge that pushed the net loss sharply higher and shrank total equity significantly.

This accumulation of losses has raised capital-impairment concerns, prompting the company to simultaneously pursue a capital reduction, rights offering and convertible bond issuance, with trading suspended due to the associated share consolidation.

The legacy biotech pipeline remains at a pre-clinical stage, and the newly added entertainment, video and logistics business purposes have not yet translated into revenue.

Going forward, the completion of the balance-sheet repair, the timing of the new-share relisting and resumption of trading, profitability trends in the legacy businesses, and whether the new businesses generate actual revenue are all points that need to be confirmed in sequence.

This report is prepared for informational purposes only and does not include a buy or sell recommendation or a target price.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.